<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126225">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02115074</url>
  </required_header>
  <id_info>
    <org_study_id>FLUVABREX-1208</org_study_id>
    <nct_id>NCT02115074</nct_id>
  </id_info>
  <brief_title>Safety of Fluvastatin-Celebrex Association in Low-grade Optico-chiasmatic Gliomas</brief_title>
  <acronym>FLUVABREX</acronym>
  <official_title>Phase I Study of Fluvastatin-Celebrex Association in Children or Adults With Optico-chiasmatic Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reliable Cancer Therapies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optico-chiasmatic gliomas have therapeutic feature since surgical resection plays a
      secondary role. Unlike other sites, many of these tumors are not amenable to complete
      resection either because of anatomical location, and sometimes they only can be biopsied. A
      substantial number of children will have recurrences following resection or will experience
      progression following incomplete tumor removal or biopsy.

      Celebrex is a Cox-2 inhibitor with anti-angiogenic and anti-tumor properties, while statins
      are known to increase the sensitivity of gliomas to anti-tumor agents. Their association
      could be administered for long periods, in the hope of much reduced risk of toxicities.

      This is a national, multicentric, interventional,  open-label, non-comparative, and
      non-randomized phase I study evaluating the maximum tolerated dose of the Fluvastatin in
      combination with fixed-dose of Celebrex.

      This project involves 10 SFCE health centers accustomed to phase I / II studies(Société
      Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent - French
      Society for the Fight against Cancer and Leukemia in Children and Adolescents).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method : the total number of patients and the number of dose levels tested will depend upon
      the safety data that occured in the previous level. A minimum of two patients will be
      included in each dose level. The second patient will be included after a sufficient time to
      assess the absence of dose-limiting toxicity in the first patient level, or within 3 weeks
      of treatment. The first cycle of the first patient must be monitored before proposing
      transistion to the next level.

      Dose escalation : the safety data for each dose level will be reviewed and discussed before
      the transition to the next level. An IDMC will meet at the end the dose escalation step, and
      will decide the possibility of extending the study to 14 additional patients at a dose level
      set below the maximum tolerated dose.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of Fluvastatine combined to a fixed-dose of Celebrex</measure>
    <time_frame>28 days (at the end of the first cycle)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The MTD is evaluated according to NCI-CTC v4.0 scale, and is defined as follows:
grade 3 or 4 neutropenia leading to a delay of therapy superior to 7 days
grade 3 or 4 thrombocytopenia requiring transfusions over a period superior to 7 days
grade 3 or 4 non-hematologic toxicities, excepted the following events:
nausea and vomiting despite appropriate symptomatic treatment,
grade 3 fever, and grade 3 liver toxicity but rapidly reversible,
grade 3 elevation of creatine phosphokinase (CPK) levels, but rapidly reversible (back &lt;3 X normal within 2 weeks after interruption of treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>During all the treatment period, for up to 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety is assessed according to NCI-CTC v4.0 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>After 3, 6, 9 and 12 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy is measured according to RANO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free</measure>
    <time_frame>during all the study (up to 1 year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>6 month-PFS overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential interactions between the two drugs</measure>
    <time_frame>Pharmacokinetics: 1 blood sample of 1.5 ml is collected  during cycle 1 and at day 1 of the second cycle before fluvastatine and celebrex administration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Fluvastatin and Celebrex are dosed on the same sample, then compared with pharmacokinetics data from the literature (when drugs are administered alone). The objective is to explore the interaction between the 2 drugs.
Pharmacokinetic analysis is performed by liquid chromatography coupled to mass spectrometry (LC/MS), with UV detection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Gliomas.</condition>
  <arm_group>
    <arm_group_label>Fluvastatine Celebrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation for Fluvastatine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatine</intervention_name>
    <description>Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.
Per os from D1 to D14 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Fluvastatine Celebrex</arm_group_label>
    <other_name>Fluvastatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex</intervention_name>
    <description>Dose levels : 100 mg twice a day (&lt; 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day  (&gt; 50 kg)
Per os from D1 to D28 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Fluvastatine Celebrex</arm_group_label>
    <other_name>Celecoxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed recurrent or progressive primary hypothalamic-chiasmatic low
             grade glioma, and not warranting a biopsy or surgery

          -  Relapsed or refractory disease after at least 1 line adjuvant treatment including
             radiation therapy, but not surgery

          -  Measurable lesions according to RANO criteria

          -  Age &gt; 6 years and &lt; 21 years old

          -  Lansky score &gt; 70 or WHO score &lt; 2 (neurological conditions associated with the
             disease should not be taken into consideration)

          -  Haematological conditions: ANC &gt; 1000/mm3 and platelets &gt; 75000/mm3

          -  Creatinine &lt; 1.5 x normal for age or calculated clearance &gt; 70 ml/mn/1.73m2

          -  Hepatic function: Total bilirubin &lt; 3 N and SGOT and SGPT &lt; 4 N

          -  Muscle enzymes : CPK &lt; 2 N

          -  No organ toxicity superior to grade 2 according to NCI-CTCAE v4.0

          -  No allergy, hypersensibility to one of the compounds of the treatment

          -  Patients able to swallow capsules

          -  Life expectancy at least &gt; 6 months

          -  Patient affiliated with a health insurance system

          -  Effective contraception for patients (male and female) with reproductive potential
             throughout the treatment period

          -  Written informed consent of patient and/or parents/guardians prior to the study
             participation

        Exclusion Criteria:

          -  Chemotherapy within 21 days before D1 of experimental treatment. This period may be
             shortened in case of previous chemotherapy with vincristine (2 weeks), or extended in
             case of targeted therapies (4 weeks), or treatment by nitrosoureas (6 weeks)

          -  Radiotherapy within 6 months before D1 of experimental treatment

          -  Peptic ulcer disease, or gastrointestinal bleeding

          -  Known hypersensitivity to sulfonamides.

          -  History of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or other
             allergic-type reactions induced by acetylsalicylic acid or NSAIDs , including COX-2
             inhibitors (cyclo-oxygenase- 2)

          -  Inflammatory bowel disease.

          -  Known congestive heart failure (NYHA II- IV)

          -  Ischemic proven, peripheral and/or history of arterial stroke (including transient
             ischemic attack)

          -  Pregnancy or breast feeding woman

          -  Known allergy to experimental treatment

          -  Organ toxicity superior to grade 2 according to NCI-CTCAE v4.0

          -  Active infection

          -  Pre-existing muscle pathology

          -  Unsuitable for medical follow-up (geographic, social or mental reasons)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre LEBLOND, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas ANDRE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital pour Enfants de &quot; La Timone &quot; AP-HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre LEBLOND, MD</last_name>
    <phone>+33(0)3 20 29 59 56</phone>
    <email>p.leblond@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas ANDRE, MD</last_name>
    <phone>+33(0)4 91 38 68 28</phone>
    <email>nicolas.andre@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de Bordeaux - Hôpital des Enfants</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline ICHER, MD</last_name>
      <phone>+33(0)5 57 82 04 38</phone>
      <email>celine.icher@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre LEBLOND, MD</last_name>
      <phone>+33(0)03 20 29 59 56</phone>
      <email>p.leblond@lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital pour enfants La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André NICOLAS, MD</last_name>
      <phone>+33(0)4 91 38 68 28</phone>
      <email>nicolas.andre@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Nantes - Hôpital Mère enfants</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadège CORRADINI, MD</last_name>
      <phone>+33(0)2 40 08 36 10</phone>
      <email>nadege.corradini@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle AERTS, MD</last_name>
      <phone>+33(0)1 44 32 43 33</phone>
      <email>isabelle.aerts@curie.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natacha ENTZ WERLE, MD</last_name>
      <phone>+33(0)3 88 12 80 94</phone>
      <email>natacha.entz-werle@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Purpan - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Isabelle BERTOZZI, MD</last_name>
      <phone>+33(0)5 34 55 86 13</phone>
      <email>bertozzi.ai@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Nancy</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal CHASTAGNER, MD</last_name>
      <phone>+33(0)3 83 15 46 37</phone>
      <email>p.chastagner@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile FAURE-CONTER, MD</last_name>
      <phone>+33(0)4 78 78 28 81</phone>
      <email>cécile.conter@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-grade gliomas, optico-chiasmatic, relapsed, refractory.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluvastatin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
